Undisclosed Neurodegeneration Program
Alzheimer's Disease, Parkinson's Disease
Pre-clinicalActive
Key Facts
About Sitala Bio
Sitala Bio is an early-stage biotech targeting the vast market of inflammation-driven diseases, with a particular emphasis on neurodegenerative conditions. The company is leveraging growing scientific evidence linking chronic inflammation to disease progression to develop first-in-class therapeutics. Operating in stealth mode from Cambridge, UK, it appears to be a privately held, pre-revenue entity in the discovery or preclinical stage, building its scientific foundation and team. Its success will hinge on validating its novel targets and translating its scientific premise into effective clinical candidates.
View full company profileTherapeutic Areas
Other Alzheimer's Disease, Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Neurodegeneration Program(s) | Muna Therapeutics | Preclinical |
| DJ-1 / PARK7 Program | Cantabio Pharmaceuticals | Pre-clinical |
| Neurodegenerative Diseases Biomarker Services | The Siesta Group | Service Offering |